Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A ribozyme-mediated approach has made it possible to replace the region in beta globin mRNA containing the sickle-cell-anaemia mutation with a gamma-globin-encoding sequence. This is an interesting new way of correcting monogenic disease, but there are major problems to overcome before it could be applied in the clinic.

More information Original publication

DOI

10.1016/s0960-9822(98)70439-7

Type

Journal article

Publication Date

1998-09-24T00:00:00+00:00

Volume

8

Pages

R696 - R698

Keywords

Anemia, Sickle Cell, Animals, Blood Viscosity, Cells, Cultured, Erythroid Precursor Cells, Fetal Hemoglobin, Genetic Therapy, Globins, Hemoglobinopathies, Humans, Mice, Mice, Transgenic, RNA, Catalytic, RNA, Messenger